Current status, challenges and future directions of drug-eluting balloons

Future Cardiology

Volumn 7, Issue 6, 2011, Pages 765-774

  Barbash, Israel M ^a   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

drug eluting balloon; in stent restenosis; paclitaxel; peripheral arterial intervention

Indexed keywords

HEPARIN; IOPROMIDE; PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS;

ANTIINFLAMMATORY ACTIVITY; BALLOON CATHETER; BARE METAL STENT; BLOOD VESSEL WALL; CELL CYCLE; CELL DIVISION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DRUG ELUTING STENT; HUMAN; HYPERPLASIA; IN VITRO STUDY; INTRAVASCULAR SPACE; NEOINTIMA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVIEW; VASCULAR LESION; VASCULAR SMOOTH MUSCLE;

ANGIOPLASTY, BALLOON, CORONARY; CORONARY DISEASE; DRUG-ELUTING STENTS; HUMANS; PROSTHESIS DESIGN; TREATMENT OUTCOME;

EID: 80555135961     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.11.56     Document Type: Review

References (43)

1. Mueller RL, Sanborn TA. The history of interventional cardiology: cardiac catheterization, angioplasty, and related interventions. Am. Heart J. 129(1), 146-172 (1995).
2. Erbel R, Haude M, Höpp HW et al. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. N. Engl. J. Med. 339(23), 1672-1678 (1998).
3. Serruys PW, de Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N. Engl. J. Med. 331(8), 489-495 (1994).
4. Hoffmann R, Mintz GS, Dussaillant GR et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 94(6), 1247-1254 (1996).
5. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349(14), 1315-1323 (2003).
6. Stone GW, Ellis SG, Cannon L et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial. JAMA 294(10), 1215-1223 (2005).
7. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: A cause for concern. Circulation 115(11), 1440-1455 discussion 1455 (2007).
8. Stone GW, Moses JW, Ellis SG et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N. Engl. J. Med. 356(10), 998-1008 (2007).
9. Kelsch B, Scheller B, Biedermann M et al. Dose response to paclitaxel-coated balloon catheters in the porcine coronary overstretch and stent implantation model. Invest. Radiol. 46(4), 255-263 (2011).
10. Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G. Paclitaxel balloon coating, a novel method ̃for prevention and therapy of restenosis. Circulation 110(7), 810-814 (2004).
11. Lovich MA, Edelman ER. Mechanisms of transmural heparin transport in the rat abdominal aorta after local vascular delivery. Circ. Res. 77(6), 1143-1150 (1995).
12. Cremers B, Speck U, Kaufels N et al. Drug-eluting balloon: very short-term exposure and overlapping. Thromb. Haemost. 101(1), 201-206 (2009).
13. Axel DI, Kunert W, Goggelmann C et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96(2), 636-645 (1997).
14. Herdeg C, Oberhoff M, Baumbach A et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J. Am. Coll. Cardiol. 35(7), 1969-1976 (2000).
15. Creel CJ, Lovich MA, Edelman ER. Arterial paclitaxel distribution and deposition. Circ. Res. 86(8), 879-884 (2000).
16. Speck U, Scheller B, Abramjuk C, Bernhardt U. Drug delivery by angiographic contrast media: inhibition of restenosis. Acad. Radiol. 12(Suppl. 1), S14-S17 (2005).
17. Cremers B, Clever Y, Schaffner S, Speck U, Bohm M, Scheller B. Treatment of coronary in-stent restenosis with a novel paclitaxel urea coated balloon. Minerva Cardioangiol. 58(5), 583-588 (2010).
18. Donaldson KL, Goolsby GL, Kiener PA, Wahl AF. Activation of p34cdc2 coincident with taxol-induced apoptosis. Cell. Growth Differ. 5(10), 1041-1050 (1994).
19. Buerke M, Guckenbiehl M, Schwertz H et al. Intramural delivery of Sirolimus prevents vascular remodeling following balloon injury. Biochim. Biophys. Acta 1774(1), 5-15 (2007).
20. Levin AD, Vukmirovic N, Hwang CW, Edelman ER. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc. Natl Acad. Sci. USA 101(25), 9463-9467 (2004).
21. Chen YW, Smith ML, Sheets M et al. Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression. J. Cardiovasc. Pharmacol. 49(4), 228-235 (2007).
22. Sheiban I, Anselmino M, Moretti C et al. Effect of a novel drug-eluted balloon coated with genistein before stent implantation in porcine coronary arteries. Clin. Res. Cardiol. 97(12), 891-898 (2008).
23. Tharp DL, Wamhoff BR, Wulff H, Raman G, Cheong A, Bowles DK. Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis. Arterioscler. Thromb. Vasc. Biol. 28(6), 1084-1089 (2008).
24. Fanggiday JC, Stella PR, Guyomi SH, Doevendans PA. Safety and efficacy of drug-eluting balloons in percutaneous treatment of bifurcation lesions: The DEBIUT (Drug-Eluting Balloon In Bifurcation Utrecht) registry. Catheter. Cardiovasc. Interv. 71(5), 629-635 (2008).
25. Dommke C, Haase KK, Suselbeck T et al. Local paclitaxel delivery after coronary stenting in an experimental animal model. Thromb. Haemost. 98(3), 674-680 (2007).
26. Albrecht T, Speck U, Baier C, Wolf KJ, Bohm M, Scheller B. Reduction of stenosis due to intimal hyperplasia after stent supported angioplasty of peripheral arteries by local administration of paclitaxel in swine. Invest. Radiol. 42(8), 579-585 (2007).
27. Nakamura T, Brott BC, Brants I et al. Vasomotor function after paclitaxel-coated balloon post-dilation in porcine coronary stent model. JACC Cardiovasc. Interv. 4(2), 247-255 (2011).
28. Joner M, Byrne RA, Lapointe JM et al. Comparative assessment of drug-eluting balloons in an advanced porcine model of coronary restenosis. Thromb. Haemost. 105(5), 864-872 (2011).
29. Scheller B, Hehrlein C, Bocksch W et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N. Engl. J. Med. 355(20), 2113-2124 (2006).
30. Scheller B, Hehrlein C, Bocksch W et al. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin. Res. Cardiol. 97(10), 773-781 (2008).
31. Unverdorben M, Vallbracht C, Cremers B et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 119(23), 2986-2994 (2009).
32. Rosenkranz S, Maier LS, Maack C, Bohm M. Hotline update of clinical trials and registries presented at the German Cardiac Society meeting 2007: 2L-Registry, Kardio-Pro, EVER, AFFECT, VTACH, ARTS II, OPTAMI, PEPCAD I, PEPCAD II, GERSHWIN, SPICE, FIX-CHF and CREDIT. Clin. Res. Cardiol. 96(7), 457-468 (2007).
33. Hehrlein C, Richardt G, Wiemer M et al. International first in man trial with novel drug eluting balloon in patients presenting with in-stent restenosis (PEPPER).J. Am. Coll. Cardiol. 57(Suppl. 14), E1640 (2011).
34. Maier LS, Maack C, Ritter O, Bohm M. Hotline update of clinical trials and registries presented at the German Cardiac Society meeting 2008. (PEPCAD, LokalTax, INH, German ablation registry, German device registry, DES.DE registry, DHR, Reality, SWEETHEART registry, ADMA, GERSHWIN).Clin. Res. Cardiol. 97(6), 356-363 (2008).
35. Cortese B, Micheli A, Picchi A et al. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart 96(16), 1291-1296 (2010).
36. Gutiérrez-Chico JL, van Geuns RJ, Koch K et al. Paclitaxel-coated balloon in combination with bare metal stent for treatment of de novo coronary lesions: an optical coherence tomography first-in-human randomised trial, balloon first vs. stent first. EuroIntervention 7(6), 711-722 (2011).
37. Herdeg C, Geisler T, Goehring-Frischholz K et al. Catheter-based local antiproliferative therapy in kissing balloon technique for in-stent stenosis of coronary artery bifurcation lesions. Can. J. Cardiol. 24(4), 309-311 (2008).
38. Sgueglia GA, Todaro D, Bisciglia A, Conte M, Stipo A, Pucci E. Kissing inflation is feasible with all second-generation drug-eluting balloons. Cardiovasc. Revasc. Med. 12(5), 280-285 (2011).
39. Mathey DG, Wendig I, Boxberger M, Bonaventura K, Kleber FX. Treatment of bifurcation lesions with a drug-eluting balloon: The PEPCAD V (Paclitaxel Eluting PTCA Balloon in Coronary Artery Disease) trial. EuroIntervention 7, K61-K65 (2011).
40. Tepe G, Zeller T, Albrecht T et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N. Engl. J. Med. 358(7), 689-699 (2008).
41. Werk M, Langner S, Reinkensmeier B et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation 118(13), 1358-1365 (2008).
42. Posa A, Hemetsberger R, Petnehazy O et al. Attainment of local drug delivery with paclitaxel-eluting balloon in porcine coronary arteries. Coron. Artery Dis. 19(4), 243-247 (2008).
43. Herdeg C, Gohring-Frischholz K, Haase KK et al. Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation. Circ. Cardiovasc. Interv. 2(4), 294-301 (2009).